 WAYNE, Pa., Nov. 04, 2020 GLOBE NEWSWIRE -- Aclaris Therapeutics, Inc. NASDAQ: ACRS, a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2020 and provided a corporate update. 